178 related articles for article (PubMed ID: 16963294)
21. Strains of Cryptococcus neoformans with defined capsular phenotypes.
Jacobson ES; Tingler MJ
J Med Vet Mycol; 1994; 32(5):401-4. PubMed ID: 7844706
[TBL] [Abstract][Full Text] [Related]
22. Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence.
Moyrand F; Fontaine T; Janbon G
Mol Microbiol; 2007 May; 64(3):771-81. PubMed ID: 17462022
[TBL] [Abstract][Full Text] [Related]
23. Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules.
Frases S; Pontes B; Nimrichter L; Viana NB; Rodrigues ML; Casadevall A
Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1228-33. PubMed ID: 19164571
[TBL] [Abstract][Full Text] [Related]
24. Quantification of C. neoformans Capsule Diameter.
Guess TE; Lai H; Nelson DE; McClelland EE
Methods Mol Biol; 2024; 2775():225-237. PubMed ID: 38758321
[TBL] [Abstract][Full Text] [Related]
25. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions.
Zaragoza O; Taborda CP; Casadevall A
Eur J Immunol; 2003 Jul; 33(7):1957-67. PubMed ID: 12884862
[TBL] [Abstract][Full Text] [Related]
27. Glucuronoxylomannan exhibits potent immunosuppressive properties.
Monari C; Bistoni F; Vecchiarelli A
FEMS Yeast Res; 2006 Jun; 6(4):537-42. PubMed ID: 16696649
[TBL] [Abstract][Full Text] [Related]
28. A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis.
Yoneda A; Doering TL
Mol Biol Cell; 2006 Dec; 17(12):5131-40. PubMed ID: 17021252
[TBL] [Abstract][Full Text] [Related]
29. Cryptococcus neoformans capsule regrowth experiments reveal dynamics of enlargement and architecture.
Wear MP; Jacobs E; Wang S; McConnell SA; Bowen A; Strother C; Cordero RJB; Crawford CJ; Casadevall A
J Biol Chem; 2022 Apr; 298(4):101769. PubMed ID: 35218774
[TBL] [Abstract][Full Text] [Related]
30. Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.
Small JM; Mitchell TG
Infect Immun; 1986 Dec; 54(3):742-50. PubMed ID: 3536747
[TBL] [Abstract][Full Text] [Related]
31. Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan.
García-Rivera J; Chang YC; Kwon-Chung KJ; Casadevall A
Eukaryot Cell; 2004 Apr; 3(2):385-92. PubMed ID: 15075268
[TBL] [Abstract][Full Text] [Related]
32. [Morphology of cell forms of visceral mycotic agents. Studies on the polysaccharide and protein histochemistry. 7. Cryptococcus neoformans].
Bader G; Bader NG
Mykosen; 1975 Aug; 18(8):327-40. PubMed ID: 1102975
[No Abstract] [Full Text] [Related]
33. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection.
Dadachova E; Bryan RA; Apostolidis C; Morgenstern A; Zhang T; Moadel T; Torres M; Huang X; Revskaya E; Casadevall A
J Infect Dis; 2006 May; 193(10):1427-36. PubMed ID: 16619191
[TBL] [Abstract][Full Text] [Related]
34. Elucidating the immunological function of the Cryptococcus neoformans capsule.
Vecchiarelli A; Pericolini E; Gabrielli E; Kenno S; Perito S; Cenci E; Monari C
Future Microbiol; 2013 Sep; 8(9):1107-16. PubMed ID: 24020739
[TBL] [Abstract][Full Text] [Related]
35. Effect of hypertonic solutes upon the polysaccharide capsule in Cryptococcus neoformans.
Jacobson ES; Tingler MJ; Quynn PL
Mycoses; 1989 Jan; 32(1):14-23. PubMed ID: 2664504
[TBL] [Abstract][Full Text] [Related]
36. Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway.
Chiapello LS; Baronetti JL; Garro AP; Spesso MF; Masih DT
Int Immunol; 2008 Dec; 20(12):1527-41. PubMed ID: 18927317
[TBL] [Abstract][Full Text] [Related]
37. Rapid in vitro capsule production by cryptococci.
Anna EJ
Am J Med Technol; 1979 Jun; 45(6):585-8. PubMed ID: 382848
[TBL] [Abstract][Full Text] [Related]
38. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.
Granger DL; Perfect JR; Durack DT
J Clin Invest; 1985 Aug; 76(2):508-16. PubMed ID: 3928681
[TBL] [Abstract][Full Text] [Related]
39. Ecto-glycanases and metabolic stability of the capsule in Cryptococcus neoformans.
Maceková D; Farkas V; Kishida E; Takeo K
J Basic Microbiol; 2006; 46(6):470-9. PubMed ID: 17139612
[TBL] [Abstract][Full Text] [Related]
40. How does Cryptococcus get its coat?
Doering TL
Trends Microbiol; 2000 Dec; 8(12):547-53. PubMed ID: 11115750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
